Lipocine (NASDAQ:LPCN) Shares Cross Below 200-Day Moving Average – Should You Sell?

Lipocine Inc. (NASDAQ:LPCN)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.71 and traded as low as $2.36. Lipocine shares last traded at $2.43, with a volume of 735,295 shares changing hands.

Analysts Set New Price Targets

A number of brokerages recently weighed in on LPCN. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Lipocine has a consensus rating of “Hold” and a consensus target price of $15.00.

Lipocine Price Performance

The firm has a market capitalization of $17.74 million, a PE ratio of -1.44 and a beta of 1.09. The stock has a 50-day moving average price of $6.92 and a 200-day moving average price of $5.71.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million.

Insider Transactions at Lipocine

In other Lipocine news, CEO Mahesh V. Patel bought 25,000 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were acquired at an average cost of $2.03 per share, with a total value of $50,750.00. Following the completion of the transaction, the chief executive officer owned 160,679 shares in the company, valued at $326,178.37. The trade was a 18.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John W. Higuchi bought 40,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The shares were acquired at an average cost of $2.03 per share, for a total transaction of $81,200.00. Following the completion of the transaction, the director owned 203,797 shares of the company’s stock, valued at approximately $413,707.91. The trade was a 24.42% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have bought 213,000 shares of company stock worth $434,600. Corporate insiders own 6.35% of the company’s stock.

Institutional Trading of Lipocine

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in Lipocine in the fourth quarter valued at about $85,000. Citadel Advisors LLC bought a new stake in Lipocine in the third quarter valued at about $41,000. Renaissance Technologies LLC increased its holdings in Lipocine by 3.6% in the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after buying an additional 1,300 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Lipocine in the fourth quarter valued at about $441,000. Finally, Geode Capital Management LLC increased its holdings in Lipocine by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after buying an additional 1,374 shares during the last quarter. 9.11% of the stock is owned by institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.